Crucell N.V. Sees Government Interest in Novel Flu Drug
Reuters -- Dutch biotech company Crucell NV plans to kick off clinical Phase I studies of an experimental antibody-based flu drug next year amid strong government interest, its chief executive said on Tuesday.